Adaptive Biotechnologies Corporation ADPT · NASDAQ
$24.02 -6.10% (-$1.56)
Summary
21 / 100 · Bulios Score
What speaks for it
- Revenue grew by 14% a year over the last 3 years.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- The company made a loss over the last 12 months.
- For every 100 USD of shareholders' equity it carries 287 USD of debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 23% a year over 5 years. Over the last 3 years it grew by 14% a year. For the next fiscal year analysts expect revenue to grow by 5.9%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $63.9M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 4
- Sell 2
Today's price within the analysts' price targets
The average target of $30.42 is 27% above today's price. 65% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2021By product
- Sequencing Revenue 51%
- Development Support Revenue 42%
- Development Revenue Regulatory Milestones 6.5%
By region
The company reports no revenue by region.
Sequencing Revenue brings in 51% of revenue. Development Revenue Regulatory Milestones grew fastest, by 124% a year.
Segments in detail